Abstract:The mammalian Nell1 gene encodes a protein kinase C-beta1 (PKC-beta1) binding protein that belongs to a new class of cell-signaling molecules controlling cell growth and differentiation. Over-expression of Nell1 in the developing cranial sutures in both human and mouse induces craniosynostosis, the premature fusion of the growing cranial bone fronts. Here, we report the generation, positional cloning and characterization of Nell1(6R), a recessive, neonatal-lethal point mutation in the mouse Nell1 gene, induced… Show more
“…It has also been reported that overexpression of NELL1 promotes apoptosis in osteoblasts both in vitro and in vivo (Zhang et al, 2003), and that this apoptotic activity may be associated with the Fas signaling pathway (Zhang et al, 2006). In NELL1 6R mutant mice, loss of NELL1 expression was associated with reduced expression of genes encoding tumor necrosis factor receptor superfamily member 11b and extracellular matrix proteins (Desai et al, 2006), which have also been implicated in human carcinogenesis (Ingber, 2002;Rowinsky, 2005). Furthermore, the high frequency (44%) of NELL1 promoter hypermethylation in colon cancer suggests a potential role for NELL1 inactivation in colon tumorigenesis (Mori et al, 2006).…”
Section: Discussionmentioning
confidence: 94%
“…The NELL1 gene encodes a protein kinase C-binding protein that contains six EGF-like domains and belongs to a new class of cell-signaling molecules controlling cell growth and differentiation (Matsuhashi et al, 1995;Watanabe et al, 1996;Kuroda and Tanizawa, 1999;Desai et al, 2006). The precise roles of NELL1 in Hypermethylation of NELL1 in esophageal cancer Z Jin et al physiology and pathophysiology remain incompletely elucidated.…”
The nel-like1 (NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma (EAC). NELL1 promoter hypermethylation was examined by real-time methylationspecific polymerase chain reaction in 259 human esophageal tissues. Hypermethylation of this promoter showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and EAC from normal esophagus (NE) (Po0.001). NELL1 normalized methylation values were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's (D) and EAC than in NE (Po0.0000001). NELL1 hypermethylation frequency was zero in NE but increased early during neoplastic progression, to 41.7% in BE from patients with Barrett's alone, 52.5% in D and 47.8% in EAC. There was a significant correlation between NELL1 hypermethylation and BE segment length. Three (11.5%) of 26 ESCCs exhibited NELL1 hypermethylation. Survival correlated inversely with NELL1 hypermethylation in patients with stages I-II (P ¼ 0.0264) but not in stages III-IV (P ¼ 0.68) EAC. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2 0 -deoxycytidine reduced NELL1 methylation and increased NELL1 mRNA expression. NELL1 mRNA levels in EACs with an unmethylated NELL1 promoter were significantly higher than those in EACs with a methylated promoter (P ¼ 0.02). Promoter hypermethylation of NELL1 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage EAC.
“…It has also been reported that overexpression of NELL1 promotes apoptosis in osteoblasts both in vitro and in vivo (Zhang et al, 2003), and that this apoptotic activity may be associated with the Fas signaling pathway (Zhang et al, 2006). In NELL1 6R mutant mice, loss of NELL1 expression was associated with reduced expression of genes encoding tumor necrosis factor receptor superfamily member 11b and extracellular matrix proteins (Desai et al, 2006), which have also been implicated in human carcinogenesis (Ingber, 2002;Rowinsky, 2005). Furthermore, the high frequency (44%) of NELL1 promoter hypermethylation in colon cancer suggests a potential role for NELL1 inactivation in colon tumorigenesis (Mori et al, 2006).…”
Section: Discussionmentioning
confidence: 94%
“…The NELL1 gene encodes a protein kinase C-binding protein that contains six EGF-like domains and belongs to a new class of cell-signaling molecules controlling cell growth and differentiation (Matsuhashi et al, 1995;Watanabe et al, 1996;Kuroda and Tanizawa, 1999;Desai et al, 2006). The precise roles of NELL1 in Hypermethylation of NELL1 in esophageal cancer Z Jin et al physiology and pathophysiology remain incompletely elucidated.…”
The nel-like1 (NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma (EAC). NELL1 promoter hypermethylation was examined by real-time methylationspecific polymerase chain reaction in 259 human esophageal tissues. Hypermethylation of this promoter showed highly discriminative receiver-operator characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and EAC from normal esophagus (NE) (Po0.001). NELL1 normalized methylation values were significantly higher in Barrett's metaplasia (BE), dysplastic Barrett's (D) and EAC than in NE (Po0.0000001). NELL1 hypermethylation frequency was zero in NE but increased early during neoplastic progression, to 41.7% in BE from patients with Barrett's alone, 52.5% in D and 47.8% in EAC. There was a significant correlation between NELL1 hypermethylation and BE segment length. Three (11.5%) of 26 ESCCs exhibited NELL1 hypermethylation. Survival correlated inversely with NELL1 hypermethylation in patients with stages I-II (P ¼ 0.0264) but not in stages III-IV (P ¼ 0.68) EAC. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2 0 -deoxycytidine reduced NELL1 methylation and increased NELL1 mRNA expression. NELL1 mRNA levels in EACs with an unmethylated NELL1 promoter were significantly higher than those in EACs with a methylated promoter (P ¼ 0.02). Promoter hypermethylation of NELL1 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage EAC.
“…24,89 In support of this concept, mice homozygous for Nell1 deficiency exhibit reduced expression of the osteoclastogenesis inhibitor osteoprotegerin, 6 and the heterozygous Nell1-deficient mice that survive to adulthood manifest an osteoporotic phenotype. 39 Interestingly, BMP2 and Wnt signaling synergistically increase osteoprotegerin expression, 90 and ongoing studies will determine whether BMP2þNELL-1 can similarly induce osteoprotegerin and/or inhibit osteoclastogenesis.…”
The differentiation factor NEL-like molecule-1 (NELL-1) has been reported as osteoinductive in multiple in vivo preclinical models. Bone morphogenetic protein (BMP)-2 is used clinically for skeletal repair, but in vivo administration can induce abnormal, adipose-filled, poorquality bone. We demonstrate that NELL-1 combined with BMP2 significantly optimizes osteogenesis in a rodent femoral segmental defect model by minimizing the formation of BMP2-induced adipose-filled cystlike bone. In vitro studies using the mouse bone marrow stromal cell line M2-10B4 and human primary bone marrow stromal cells have confirmed that NELL-1 enhances BMP2-induced osteogenesis and inhibits BMP2-induced adipogenesis. Importantly, the ability of NELL-1 to direct BMP2-treated cells toward osteogenesis and away from adipogenesis requires intact canonical Wnt signaling. Overall, these studies establish the feasibility of combining NELL-1 with BMP2 to improve clinical bone regeneration and provide mechanistic insight into canonical Wnt pathway activity during NELL-1 and BMP2 osteogenesis. The novel abilities of NELL-1 to stimulate Wnt signaling and to repress adipogenesis may highlight new treatment approaches for bone loss in osteoporosis. NEL-like molecule-1 (NELL-1) is an osteoinductive growth factor first identified through its overexpression in pathologically fusing suture specimens from patients with craniosynostosis. 1,2 Transgenic Nell1-overexpressing mice recapitulate craniosynostosis-like phenotypes, exhibiting gross calvarial bone overgrowth and increased osteoblast differentiation. 3 Conversely, Nell1 deficiency severely disrupts bone growth, as mice with nonsense mutations in Nell1 die perinatally with major skeletal anomalies in the craniofacial complex, spine, and long bones. 4e6 Highlighting the central role of NELL-1 in skeletal development, NELL-1 mediates key downstream effects of the master osteogenic regulator runt-related transcription factor 2 (RUNX2) 7 and can partially rescue RUNX2 loss of function. 8 NELL-1 can also transiently activate mitogen-activated protein kinase signaling to induce RUNX2 phosphorylation and osteogenic differentiation. 9 Recently, we
“…(13) In addition, Nell-1 overexpression results in abnormal cartilage formation, (14) whereas loss of Nell-1 function results in reduced gene expression of extracellular matrix proteins critical for osteogenesis and chondrogenesis. (15) In this study we revealed roles for Nell-1 in the molecular regulation of chondrogenesis using ATDC5 cells, a murine embryonal carcinoma-derived chondroprogenitor cell line that undergoes a multistep chondrogenic differentiation process beginning with mesenchymal condensation and culminating in cartilage formation in vitro. (16,17) The ATDC5 cell line is a commonly used model for dissecting molecular mechanisms underlying the regulation of chondrocyte differentiation during endochondral bone formation.…”
Section: Introductionmentioning
confidence: 95%
“…Nell1-deficient neonatal mice (15) and wild-type littermates were euthanized and fixed in 10% formalin, and femurs were isolated and embedded in paraffin. Mouse embryos were collected from pregnant C57BL/6 mice, where age was defined as E0.5 on the day the vaginal plug was observed.…”
Nell-1 is a growth factor required for normal skeletal development and expression of extracellular matrix proteins required for bone and cartilage cell differentiation. We identified the transcription factor nuclear factor of activated T cells (Nfatc2) as a primary response gene of Nell-1 through a microarray screen, with validation using real-time polymerase chain reaction (PCR). We investigated the effects of recombinant Nell-1 protein on the chondrogenic cell line ATDC5 and primary mouse chondrocytes. The osteochondral transcription factor Runx2 was investigated as a possible intermediary between Nell-1 and Nfatc2 using adenoviral overexpression of wild-type and dominant-negative Runx2. Nell-1 transiently induced both transcription and translation of Nfatc2, an effect inhibited by transduction of dominant-negative Runx2, suggesting that Runx2 was necessary for Nfatc2 induction. Differentiation assays revealed inhibitory effects of Nell-1 on ATDC5 cells. Although proliferation was unaffected, expression of chondrocyte-specific genes was decreased, and cartilage nodule formation and proteoglycan accumulation were suppressed. siRNA knockdown of Nfatc2 significantly reversed these inhibitory effects. To elucidate the relationship between Nell-1, Runx2, and Nfatc2 in vivo, their presence and distribution were visualized in femurs of wild-type and Nell1-deficient mice at both neonatal and various developmental stages using immunohistochemistry. All three proteins colocalized in the perichondrium of wild-type femurs but stained weakly or were completely absent in Nell1-deficient femurs at neonatal stages. Thus Nfatc2 likely plays an important role in Nell-1-mediated osteochondral differentiation in vitro and in vivo. To our knowledge, this is the first demonstration that Nfatc2 is a primary response gene of Nell-1. ß
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.